More than 65% of patients with germline BRCA/PALB2-mutated pancreatic ductal adenocarcinoma responded to treatment with combination cisplatin and gemcitabine, according to results of a study reported in the Journal of Clinical Oncology. Two- and three-year survival rates reached 31% and 18%, respectively.
Approximately 53,000 cases of oral and oropharyngeal cancer are diagnosed in the United States each year. Men are twice as likely to develop the disease, and it typically affects people older than 55.
In early March, I developed fatigue, mild shortness of breath, and a dry cough, so, following Centers for Disease Control and Prevention (CDC) recommendations, I called the triage line at my primary care clinic. The nurse with whom I spoke offered me an appointment that same day.
Healthcare workers in the United States accounted for 20% of all deaths caused by the COVID-19 coronavirus pandemic to date. The Guardian and Kaiser Health News partnered to document every healthcare worker who’s died from COVID-19 in response to the absence of a reliable nationwide database.
On April 17, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pemigatinib (Pemazyre™), the first treatment approved for adults with certain types of previously treated advanced cholangiocarcinoma.
On April 17, 2020, as part of Project Orbis, the U.S. Food and Drug Administration (FDA) approved tucatinib (Tukysa™) in combination with chemotherapy (trastuzumab and capecitabine) for the treatment of adult patients with advanced forms of HER2-positive breast cancer that can’t be removed with surgery or have spread to other parts of the body, including the brain, and who have received one or more prior treatments.
Oncology nurses must advocate for prevention and control of the COVID-19 coronavirus to minimize the risk to themselves and the patients with cancer in their care, the International Society of Nurses in Cancer Care (ISNCC) announced in its April 2, 2020, COVID-19 Position Statement. ONS is a full member of ISNCC.
As oncology nurses in Chicago, IL, on the front lines of the COVID-19 coronavirus pandemic in the United States, fear, anxiety, anger, and frustration are just some of the emotions that have been festering in me and my coworkers since the beginning of 2020. It seems like an endless era, and I’m scared: for my patients, coworkers, and family.
On April 15, 2020, the U.S. Food and Drug Administration (FDA) approved mitomycin (Jelmyto®) for the treatment of adult patients with low-grade, upper-tract urothelial cancer (LG-UTUC).
Two new drugs in clinical trials are extending survival for women with metastatic HER2-positive breast cancer that had progressed with previous treatment. One of the drugs was effective for brain metastasis, which is particularly difficult to treat. Results from both studies were reported in the New England Journal of Medicine.